Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fan Yu

Showing results (951-960 of 969) with videos related to

Pageof 97
Sort By:
Cancer Immunology, Immunotherapy : CII|August 7, 2024
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunityAurelie Herault, Judy Mak, Josefa de la Cruz-Chuh, et al.
Cancer Research|March 5, 2009
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selectionAndrew G Polson, Jill Calemine-Fenaux, Pamela Chan, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Journal of Medicinal Chemistry|February 5, 2019
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple MyelomaXiaojing Wang, Wesley Blackaby, Vivienne Allen, et al.
Molecular Cancer Therapeutics|February 23, 2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide LinkersThomas H Pillow, Melissa Schutten, Shang-Fan Yu, et al.
Chemmedchem|November 2, 2019
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo ActivityThomas H Pillow, Pragya Adhikari, Robert A Blake, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Lancet (London, England)|July 18, 2017
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trialStephen Russell, Jean Bennett, Jennifer A Wellman, et al.
Surgical Neurology|October 13, 2009
Clinical practice guidelines in severe traumatic brain injury in TaiwanKuo-Hsing Liao, Cheng-Kuei Chang, Hong-Chang Chang, et al.
Molecular Pharmaceutics|July 25, 2018
Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug ConjugatesZhonghua Pei, Chunjiao Chen, Jinhua Chen, et al.
Pageof 97

Showing results (951-960 of 969) with videos related to

Sort By:
Pageof 97
Cancer Immunology, Immunotherapy : CII|August 7, 2024
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunityAurelie Herault, Judy Mak, Josefa de la Cruz-Chuh, et al.
Cancer Research|March 5, 2009
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selectionAndrew G Polson, Jill Calemine-Fenaux, Pamela Chan, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Journal of Medicinal Chemistry|February 5, 2019
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple MyelomaXiaojing Wang, Wesley Blackaby, Vivienne Allen, et al.
Molecular Cancer Therapeutics|February 23, 2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide LinkersThomas H Pillow, Melissa Schutten, Shang-Fan Yu, et al.
Chemmedchem|November 2, 2019
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo ActivityThomas H Pillow, Pragya Adhikari, Robert A Blake, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Lancet (London, England)|July 18, 2017
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trialStephen Russell, Jean Bennett, Jennifer A Wellman, et al.
Surgical Neurology|October 13, 2009
Clinical practice guidelines in severe traumatic brain injury in TaiwanKuo-Hsing Liao, Cheng-Kuei Chang, Hong-Chang Chang, et al.
Molecular Pharmaceutics|July 25, 2018
Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug ConjugatesZhonghua Pei, Chunjiao Chen, Jinhua Chen, et al.
Pageof 97